C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is thrilled to announce the launch of PatientSeek, a groundbreaking precision medicine platform. This platform is the result of a successful research collaboration between C4X Discovery and the renowned Garvan Institute of Medical Research, and promises to revolutionize the world of medicine.
In an exciting collaboration between C4XD and Garvan Institute, a revolutionary genetic signature was used to analyse a failed Phase 3 Parkinson’s clinical trial. Unexpectedly, PatientSeek identified a subgroup of participants that responded to the drug, providing insights into the disease that have the potential to help match treatments with the patients who are most likely to benefit, speeding up the drug development process.
The PatientSeek platform has proven itself as a powerful tool for targeting and optimising patient selection in clinical trials, offering a novel approach for identifying patient subgroups for complex genetic diseases. This study, focused on Parkinson’s disease, has validated the utility of the platform for the first time, potentially paving the way for enhanced success in clinical trials. This research will be submitted to a peer-reviewed journal for publication soon, offering a critical insight into the potential of the PatientSeek platform.
Associate Professor Antony Cooper, Research Director of the Australian Parkinson’s Mission and Garvan research partner, has hailed this new development as highly significant – not only does it prove that the subgroups identified by PatientSeek are clinically relevant, but it also reaffirms genetics’ role in Parkinson’s disease and response to treatment. By uncovering these distinctions, the Australian Parkinson’s Mission has made a crucial step towards precision medicine that can identify effective treatments tailored to the individual. With this exciting new finding, the next focus will be to delve deeper into the differences between the identified subgroups, allowing us to gain an even greater understanding of the disease’s heterogeneity.
Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, is excited about the potential of the groundbreaking work being done at the Garvan Institute. He believes that this discovery could revolutionise clinical trial design by enabling the development of companion diagnostics, which in turn could help stratify patients according to their likelihood of responding to specific therapeutics. This is an important milestone in bringing precision medicine to those living with Parkinson’s.
C4XD is proud to announce the successful launch of its new PatientSeek platform, a result of collaborating with the Garvan Institute to utilize their Taxonomy3® technology. PatientSeek has the potential to revolutionize precision medicine approaches by using a unique mathematical approach to stratify patients according to their genetics in order to identify novel treatments. Already, C4XD has identified PatientSeek subgroups in immuno-inflammatory diseases and is looking forward to exploring their applications further.